Novartis In-Licenses PTCT's Huntington's Disease Drug for $2.9 Billion
Novartis will make an upfront payment of $1.0 billion to PTCT and the latter will also be eligible for up to $1.9 billion in ...
precisionmedicineonline1d
Novartis Pens $2.9B Deal With PTC Therapeutics for Huntington's Disease Drug
Novartis licensed PTC's PTC518 Huntington's disease program and related molecules and will pay $1 billion upfront as well as other costs.
Stocktwits on MSN1d
PTC Therapeutics Stock Eyes Further Rally After Price-Target Hikes On Huntington’s Therapy Deal With Novartis: Retail Buzz Grows
Shares of PTC Therapeutics Inc. climbed nearly 1% pre-market Tuesday, poised to extend their rally to levels last seen in ...
biopharma-reporter1d
PTC Therapeutics boosted by Novartis rights deal for Huntington’s program
The potential $2.9 billion deal stands the New Jersey company in good stead after recent disappointing results in its ALS ...
Pharmabiz1d
PTC Therapeutics inks global license and collaboration agreement with Novartis for PTC518 Huntington's disease programme
PTC Therapeutics inks global license and collaboration agreement with Novartis for PTC518 Huntington's disease programme: Warren, New Jersey Tuesday, December 3, 2024, 14:00 Hrs [ ...
Daily1d
Novartis bolsters Neuroscience pipeline with in-licensing of PTC518 for Huntington's disease
Basel: Novartis has announced that it has entered into a global license and collaboration agreement with PTC Therapeutics for ...
PTC Therapeutics’ Novartis deal expedites value creation, says Wells Fargo
Wells Fargo keeps an Overweight rating and $68 price target on PTC Therapeutics (PTCT). Investors had been undervaluing the potential value of ...
BioWorld1d
Phase II Huntington’s tie-up with Novartis could edge $3B for PTC
PTC Therapeutics Inc. said a “highly competitive process with several parties involved” led to the deal centered on the ...
MedPage Today2d
Beta-Blockers Tied to Delayed Huntington's Disease Progression
The disease is characterized by progressive motor, cognitive, and psychiatric decline. Three treatments are approved to treat ...
Hosted on MSN2d
PTC Therapeutics Scores A $2.9 Billion Novartis Deal And Tops Profit-Taking Zone
Novartis will pay PTC Therapeutics up to $2.9 billion in a licensing deal for its Huntington's treatment. PTC Therapeutics stock surged.
GEN2d
Novartis, PTC Ink Up-to-$2.9B Huntington’s Disease Collaboration
Novartis will partner with PTC Therapeutics to develop PTC’s PTC518 Huntington's disease program and an unspecified number of related molecules, through an up-to-$2.9 billion exclusive global license ...
PTC upgraded to outperform by RBC on Novartis deal
RBC Capital has upgraded PTC Therapeutics (PTCT) to outperform from sector perform on the company’s deal with Novartis (NVS) for its Huntington’s disease program. Read more here.